var data={"title":"Abciximab: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Abciximab: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5545?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=abciximab-patient-drug-information\" class=\"drug drug_patient\">see &quot;Abciximab: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F128991\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>ReoPro</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F128992\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>ReoPro</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F129024\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antiplatelet Agent, Glycoprotein IIb/IIIa Inhibitor</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F128994\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Percutaneous coronary intervention (PCI):</b> IV: 0.25 mg/kg bolus administered 10 to 60 minutes prior to start of PCI followed by an infusion of 0.125 mcg/kg/minute (maximum: 10 mcg/minute) for 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Unstable angina/non-ST-elevation MI (UA/NSTEMI) unresponsive to conventional medical therapy with planned PCI within 24 hours:</b> IV: 0.25 mg/kg bolus followed by an 18- to 24-hour infusion of 10 mcg/minute, concluding 1 hour after PCI.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>ST-elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI) (off-label use) (ACCF/AHA [O'Gara 2013]):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Loading dose: 0.25 mg/kg bolus administered at the time of PCI</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Maintenance infusion: 0.125 mcg/kg/minute (maximum: 10 mcg/minute) continued for up to 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Intracoronary (off-label route): 0.25 mg/kg bolus administered directly to the site of the infarct lesion; may be followed with an intravenous maintenance infusion if refractory intraprocedural thrombotic complications occur (Stone 2012)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F128995\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15671238\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">There are no dosage adjustments provided in the manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hemodialysis: Dialyzable: Unknown, but unlikely (NCS/SCCM [Frontera 2016])</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15671239\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F128975\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">ReoPro: 2 mg/mL (5 mL) [contains polysorbate 80]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F128960\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F128978\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">For IV administration. Solution must be filtered using a 0.2 or 5 micron low protein-binding syringe filter during preparation or via a 0.2 to 0.22 micron low protein-binding inline filter during administration. Do not shake vial.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Intracoronary administration (off-label route): In select STEMI cases (eg, anterior STEMI), abciximab bolus may be administered through the guiding catheter directly to the culprit lesion site (Stone 2012; Thiele 2012)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14471247\" class=\"block uica drugH1Div\"><span class=\"drugH1\">Usual Infusion Concentrations: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>IV infusion:</b> 7.2 mg in 250 mL (concentration: 28.8 <b>mcg</b>/mL) <b>or</b> 9 mg in 250 mL (concentration: 36 <b>mcg</b>/mL) of D<sub>5</sub>W or NS</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F128976\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Percutaneous coronary intervention:</b> Prevention of cardiac ischemic complications in patients undergoing percutaneous coronary intervention (PCI)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Unstable angina/non-ST-elevation myocardial infarction: </b>Prevention of cardiac ischemic complications in patients with unstable angina (UA)/non-ST-elevation myocardial infarction (NSTEMI) unresponsive to conventional therapy when PCI is scheduled within 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> Intended for use with aspirin and heparin, at a minimum. Safety and efficacy of abciximab use in patients not undergoing PCI have not been established.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Guideline recommendations: </i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>NSTEMI: </i>In patients with non-ST-elevation acute coronary syndrome (NSTE-ACS) treated with an early invasive strategy and dual antiplatelet therapy with intermediate/high-risk features (eg, positive troponin), the preferred GP IIb/IIIa inhibitors that may be considered as part of initial antiplatelet therapy are eptifibatide or tirofiban (ACC/AHA [Amsterdam 2014]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25483778\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>ST-elevation myocardial infarction (STEMI) undergoing primary PCI</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5174499\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\"> The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F128967\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">As with all drugs which may affect hemostasis, bleeding is associated with abciximab. Hemorrhage may occur at virtually any site. Risk is dependent on multiple variables, including the concurrent use of multiple agents which alter hemostasis and patient susceptibility.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Hypotension (14%), chest pain (11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (14%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Minor hemorrhage (4% to 17%), major hemorrhage (1% to 14%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Back pain (18%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Antibody development (HACA, first exposure: 6%; readministration: 27%; four or more exposures: 44%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Bradycardia (5%), peripheral edema (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Abdominal pain (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Thrombocytopenia: &lt;100,000 cells/mm<sup>3</sup> (3% to 6%); &lt;50,000 cells/mm<sup>3</sup> (0.4% to 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Pain at injection site (4%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%: Abdominal distension, abnormality in thinking, abscess, agitation, allergic reaction (possible), anaphylaxis (possible), anemia, anxiety, arteriovenous fistula, bladder pain, bronchitis, bronchospasm, bullous skin disease, cellulitis, cerebrovascular accident, cold extremities, coma, complete atrioventricular block, confusion, diabetes mellitus, diaphoresis, diarrhea, diplopia, dizziness, dyspepsia, dysuria, edema, embolism, gastroesophageal reflux disease, hyperkalemia, hypertonia, hypoesthesia, incisional pain, incomplete atrioventricular block, inflammation, intestinal obstruction, intracranial hemorrhage, leukocytosis, muscle spasm, myalgia, nodal arrhythmia, pain, pallor, palpitations, petechiae, pleural effusion, pleurisy, pneumonia, prostatitis, pruritus, pseudoaneurysm, pulmonary alveolar hemorrhage, pulmonary embolism, rales, renal insufficiency, rhonchi, thrombophlebitis, urinary frequency, urinary incontinence, urinary retention, ventricular tachycardia, visual disturbance, weakness, wound, xerostomia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F128981\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to abciximab, murine proteins, or any component of the formulation; active internal hemorrhage or recent (within 6 weeks) clinically-significant GI or GU bleeding; history of cerebrovascular accident within 2 years or with significant residual neurological deficit; bleeding diathesis; administration of oral anticoagulants within 7 days unless prothrombin time (PT) is &le;1.2 times control PT value; thrombocytopenia (&lt;100,000 cells/mcL); recent (within 6 weeks) major surgery or trauma; intracranial tumor, arteriovenous malformation, or aneurysm; severe uncontrolled hypertension; history of vasculitis (presumed or documented); use of dextran before PCI or intent to use dextran during PCI.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F128964\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anaphylaxis/hypersensitivity reactions: Administration may result in human antichimeric antibody formation that can cause hypersensitivity reactions (including anaphylaxis [rare], sometimes fatal).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bleeding: The most common complication is bleeding, including retroperitoneal, pulmonary, and spontaneous GI and/or GU bleeding; monitor closely for bleeding, especially the arterial access site for the cardiac catheterization. Use with extreme caution in patients with platelet counts &lt;150,000/mm<sup>3</sup>, hemorrhagic retinopathy, previous history of GI disease, recent thrombolytic therapy and in chronic dialysis patients. Use caution with administration of other drugs affecting hemostasis. Minimize other procedures, including arterial and venous punctures, IM injections, use of urinary catheters, nasogastric tubes, and automatic blood pressure cuffs. Increased risk of hemorrhage during or following angioplasty is associated with unsuccessful PCI, PCI procedure &gt;70 minutes duration, or PCI performed within 12 hours of symptom onset for acute myocardial infarction. When attempting IV access, avoid noncompressible sites (eg, subclavian or jugular veins). If serious uncontrolled bleeding or the need for emergency surgery arises, discontinue abciximab.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thrombocytopenia: Administration may result in human antichimeric antibody formation that can cause thrombocytopenia, including severe cases; immediately discontinue if thrombocytopenia occurs. Readministration within 30 days or in patients with human antichimeric antibodies (HACA) increases the incidence and severity of thrombocytopenia.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Use with caution in patients &gt;65 years; may have increased risk of bleeding.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Low weight patients: Use with caution in patients weighing &lt;75 kg; may have increased risk of bleeding.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Diminished efficacy: Administration may result in human antichimeric antibody formation that can cause diminished efficacy upon readministration.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Sheath removal: Discontinuation of heparin immediately upon completion of the procedure and removal of the sheath within 6 hours is strongly recommended as long as ACT &lt;150 to 180 seconds or aPTT &lt;50 seconds (ACCF/AHA/SCAI [Levine 2011]). Use standard compression techniques after sheath removal. Monitor the site closely afterwards for further bleeding.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Surgery: Discontinue &ge;12 hours prior to coronary artery bypass graft surgery (ACC/AHA [Amsterdam 2014]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298628\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F128969\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9204&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the antiplatelet effect of other Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anticoagulants: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Apixaban: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Apixaban. Specifically, the risk for bleeding may be increased.  Management: Carefully consider risks and benefits of this combination and monitor closely.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Belimumab: Monoclonal Antibodies may enhance the adverse/toxic effect of Belimumab. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cephalothin: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Cephalothin. Specifically, the risk for bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Collagenase (Systemic): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabigatran Etexilate: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Dabigatran Etexilate. Agents with Antiplatelet Properties may increase the serum concentration of Dabigatran Etexilate. This mechanism applies specifically to clopidogrel.  Management: Carefully consider risks and benefits of this combination and monitor closely; Canadian labeling recommends avoiding prasugrel or ticagrelor.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dasatinib: May enhance the anticoagulant effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deoxycholic Acid: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Deoxycholic Acid. Specifically, the risk for bleeding or bruising in the treatment area may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dextran: May enhance the anticoagulant effect of Abciximab.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Edoxaban: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Edoxaban. Specifically, the risk of bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Glucosamine: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Bleeding may occur.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ibritumomab Tiuxetan: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab Tiuxetan. Both agents may contribute to impaired platelet function and an increased risk of bleeding. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ibrutinib: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Limaprost: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Fluoride (with ADE): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with AE, No Iron): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obinutuzumab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Obinutuzumab. Specifically, the risk of serious bleeding-related events may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Omega-3 Fatty Acids: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentosan Polysulfate Sodium: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of bleeding may be increased by concurrent use of these agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentoxifylline: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prostacyclin Analogues: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rivaroxaban: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Rivaroxaban.  Management: Carefully consider risks and benefits of this combination and monitor closely; Canadian labeling recommends avoiding prasugrel or ticagrelor.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Salicylates: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Salicylates. Increased risk of bleeding may result. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thrombolytic Agents: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tipranavir: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Urokinase: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin E (Systemic): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F128971\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F128983\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted. In vitro studies have shown only small amounts of abciximab to cross the placenta (Miller 2003). Information related to the use of abciximab in pregnancy is limited (Santiago-Diaz 2009; Sebastian 1998).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20517875\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if abciximab is present in breast milk. The manufacturer recommends that caution be exercised when administering abciximab to breastfeeding women.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F128973\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Prothrombin time, activated partial thromboplastin time (aPTT), hemoglobin, hematocrit, platelet count, fibrinogen, fibrin split products, transfusion requirements, signs of hypersensitivity reactions, guaiac stools, Hemastix urine. Platelet count should be monitored at baseline, 2 to 4 hours following bolus infusion, and at 24 hours (or prior to discharge, if before 24 hours). To minimize risk of bleeding:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Abciximab initiated 18 to 24 hours prior to PCI: Maintain aPTT between 60 to 85 seconds during the heparin/abciximab infusion period</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">During PCI: Maintain ACT between 200 to 300 seconds</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Following PCI (if anticoagulation is maintained): Maintain aPTT between 50 to 75 seconds</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sheath removal should not occur until aPTT is &le;50 seconds or ACT &le;175 seconds.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Maintain bleeding precautions, avoid unnecessary arterial and venous punctures, use saline or heparin lock for blood drawing, assess sheath insertion site and distal pulses of affected leg every 15 minutes for the first hour and then every 1 hour for the next 6 hours if femoral access utilized for percutaneous coronary intervention. Arterial access site care is important to prevent bleeding. Care should be taken when attempting vascular access that only the anterior wall of the femoral artery is punctured, avoiding a Seldinger (through and through) technique for obtaining sheath access. Femoral vein sheath placement should be avoided unless needed. While the vascular sheath is in place, patients should be maintained on complete bedrest with the head of the bed at a 30&deg; angle and the affected limb restrained in a straight position.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Observe patient for mental status changes, hemorrhage; assess nose and mouth mucous membranes, puncture sites for oozing, ecchymosis, and hematoma formation; examine urine, stool, and emesis for presence of occult or frank blood; gentle care should be provided when removing dressings.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F128963\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Fab antibody fragment of the chimeric human-murine monoclonal antibody 7E3; this agent binds to platelet IIb/IIIa receptors, resulting in steric hindrance, thus inhibiting platelet aggregation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F128980\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset: Rapid; platelet aggregation reduced to &lt;20% of baseline at 10 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration: Platelet function recovery: 24 to 48 hours (Tcheng 1994; Mascelli 1998); may be up to 72 hours for restoration of normal hemostasis (Schror 2003). Platelet function may remain abnormal for up to 7 days post infusion based on shear-dependent platelet function testing as opposed to platelet aggregometry (Osende 2001).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>: 0.07 L/kg (Schror 2003)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: Mostly bound to GP IIb/IIIa receptors on platelet surface</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Unbound abciximab metabolized via proteolytic cleavage (Schror 2003)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Plasma: ~30 minutes; dissociation half-life from GP IIb/IIIa receptors: up to 4 hours (Schror 2003). <b>Note:</b> 29% and 13% of abciximab estimated to remain on GP IIb/IIIa receptors at 8 and 15 days, respectively (Mascelli 1998)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak: Platelet inhibition: ~30 minutes (Mascelli 1998)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16322956\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (ReoPro Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 mg/mL (5 mL): $1,617.82</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F128984\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Clotinab (KR, PY, TH);</li>\n      <li>ReoPro (AR, AT, AU, BB, BE, BG, BR, CH, CL, CO, CZ, DE, DK, ES, FI, FR, GB, GR, HK, HU, IE, IN, IS, IT, KR, LK, LU, MX, NL, NO, NZ, PE, PK, PL, PT, RU, SE, SG, SI, TH, TW, ZA);</li>\n      <li>Reopro (CN)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Aguirre FV, Topol EJ, and Ferguson JJ, &ldquo;Bleeding Complications With the Chimeric Antibody to Platelet Glycoprotein IIb/IIIa Intergrin in Patients Undergoing Percutaneous Coronary Intervention. EPIC Investigators,&rdquo; <i>Circulation</i>, 1995, 91(12):2882-90.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/abciximab-drug-information/abstract-text/7796496/pubmed\" target=\"_blank\" id=\"7796496\">7796496</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Amsterdam EA, Wenger NK, Brindis RG, et al; American College of Cardiology; American Heart Association Task Force on Practice Guidelines; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons; American Association for Clinical Chemistry. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines [published correction appears in <i>J Am Coll Cardiol</i>. 2014;64(24):2713-2714]. <i>J Am Coll Cardiol</i>. 2014;64(24):e139-e228. doi: 10.1016/j.jacc.2014.09.017.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/abciximab-drug-information/abstract-text/25260718/pubmed\" target=\"_blank\" id=\"25260718\">25260718</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Antman EM, Giugliano RP, Gibson CM, et al, &ldquo;Abciximab Facilitates the Rate and Extent of Thrombolysis: Results of the Thrombolysis in Myocardial Infarction (TIMI) 14 Trial. The TIMI 14 Investigators,&rdquo; <i>Circulation</i>, 1999, 99(21):2720-32.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/abciximab-drug-information/abstract-text/10351964/pubmed\" target=\"_blank\" id=\"10351964\">10351964</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &ldquo;ASSENT-3 Investigators. Efficacy and Safety of Tenecteplase in Combination With Enoxaparin, Abciximab, or Unfractionated Heparin: The ASSENT-3 Randomised Trial in Acute Myocardial Infarction,&rdquo; <i>Lancet</i>, 2001, 358 (9282):605-13.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/abciximab-drug-information/abstract-text/11530146/pubmed\" target=\"_blank\" id=\"11530146\">11530146</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Berkowitz SD, Harrington RA, Rund MM, et al, &ldquo;Acute Profound Thrombocytopenia After C7E3 Fab (Abciximab) Therapy,&rdquo; <i>Circulation</i>, 1997, 95(4):809-13.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/abciximab-drug-information/abstract-text/9054735/pubmed\" target=\"_blank\" id=\"9054735\">9054735</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brener SJ, Barr LA, Burchenal JE, et al, &ldquo;Randomized, Placebo-Controlled Trial of Platelet Glycoprotein IIb/IIIa Blockade With Primary Angioplasty for Acute Myocardial Infarction,&rdquo; ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators, <i>Circulation</i>, 1998, 98(8):734-41.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ellis SG, Tendera M, de Belder MA, et al, &ldquo;Facilitated PCI in Patients With ST-Elevation Myocardial Infarction,&rdquo; <i>N Engl J Med</i>, 2008, 358(21):2205-17.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/abciximab-drug-information/abstract-text/18499565/pubmed\" target=\"_blank\" id=\"18499565\">18499565</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ferraris VA, Saha SP, Oestreich JH, et al, &ldquo;2012 Update to the Society of Thoracic Surgeons Guideline on Use of Antiplatelet Drugs in Patients Having Cardiac and Noncardiac Operations,&rdquo; <i>Ann Thorac Surg</i>, 2012, 94(5):1761-81.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/abciximab-drug-information/abstract-text/23098967/pubmed\" target=\"_blank\" id=\"23098967\">23098967</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Frontera JA, Lewin JJ 3rd, Rabinstein AA, et al; Guideline for reversal of antithrombotics in intracranial hemorrhage: a statement for healthcare professionals from the Neurocritical Care Society and Society of Critical Care Medicine. <i>Neurocrit Care.</i> 2016;24(1):6-46.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/abciximab-drug-information/abstract-text/26714677/pubmed\" target=\"_blank\" id=\"26714677\">26714677</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Giugliano RP, &ldquo;Drug-Induced Thrombocytopenia: Is It a Serious Concern for Glycoprotein IIb/IIIa Receptor Inhibitors?&rdquo; <i>J Thromb Thrombolysis</i>, 1998, 5(3):191-202.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/abciximab-drug-information/abstract-text/10767115/pubmed\" target=\"_blank\" id=\"10767115\">10767115</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hamm CW, Heeschen C, Goldmann B, et al, &ldquo;Benefit of Abciximab in Patients With Refractory Unstable Angina in Relation to Serum Troponin T Levels. c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators,&rdquo; <i>N Engl J Med</i>, 1999, 340(21):1623-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/abciximab-drug-information/abstract-text/10341274/pubmed\" target=\"_blank\" id=\"10341274\">10341274</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Huxtable LM, Tafreshi MJ, and Rakkar AN, &ldquo;Frequency and Management of Thrombocytopenia With the Glycoprotein IIb/IIIa Receptor Antagonists,&rdquo; <i>Am J Cardiol</i>, 2006, 97(3):426-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/abciximab-drug-information/abstract-text/16442410 /pubmed\" target=\"_blank\" id=\"16442410 \">16442410 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jubelirer SJ, Koenig BA, and Bates MC, &ldquo;Acute Profound Thrombocytopenia Following C7E3 Fab (Abciximab) Therapy: Case Reports, Review of the Literature and Implications for Therapy,&rdquo; <i>Am J Hematol</i>, 1999, 61(3):205-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/abciximab-drug-information/abstract-text/10398314/pubmed\" target=\"_blank\" id=\"10398314\">10398314</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kastrati A, Mehilli J, Neumann FJ, et al, &ldquo;Abciximab in Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention After Clopidogrel Pretreatment,&rdquo; <i>JAMA</i>, 2006, 295(3):1531-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/abciximab-drug-information/abstract-text/16533938/pubmed\" target=\"_blank\" id=\"16533938\">16533938</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Keeley EC, Boura JA, and Grines CL, &ldquo;Comparison of Primary and Facilitated Percutaneous Coronary Interventions for ST-elevation Myocardial Infarction: Quantitative Review of Randomised Trials,&rdquo; <i>Lancet</i>, 2006, 367(9510):579-88.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/abciximab-drug-information/abstract-text/16488801/pubmed\" target=\"_blank\" id=\"16488801\">16488801</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Levine GN, Bates ER, Blankenship JC, et al, &ldquo;2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions,&rdquo; <i>Circulation</i>, 2011, 124(23):e574-651.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/abciximab-drug-information/abstract-text/22064601/pubmed\" target=\"_blank\" id=\"22064601\">22064601</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lincoff AM, Califf RM, Anderson KM, et al, &ldquo;Evidence for Prevention of Death and Myocardial Infarction With Platelet Membrane Glycoprotein IIb/IIIa Receptor Blockade by Abciximab (c7E3 Fab) Among Patients With Unstable Angina Undergoing Percutaneous Coronary Revascularization. EPIC Investigators. Evaluation of 7E3 in Preventing Ischemic Complications,&rdquo; <i>J Am Coll Cardiol</i>, 1997, 30(1):149-56.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/abciximab-drug-information/abstract-text/9207636/pubmed\" target=\"_blank\" id=\"9207636\">9207636</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lincoff AM, Califf RM, Moliterno DJ, et al, &ldquo;Complementary Clinical Benefits of Coronary-Artery Stenting and Blockade of Platelet Glycoprotein IIb/IIIa Receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators,&rdquo; <i>N Engl J Med</i>, 1999, 341(5):319-27.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/abciximab-drug-information/abstract-text/10423466/pubmed\" target=\"_blank\" id=\"10423466\">10423466</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lincoff AM, Califf RM, Van de Werf F, et al, &ldquo;Mortality at 1 Year With Combination Platelet Glycoprotein IIb/IIIa Inhibition and Reduced-Dose Fibrinolytic Therapy vs Conventional Fibrinolytic Therapy for Acute Myocardial Infarction: GUSTO V Randomized Trial,&rdquo; <i>JAMA</i>, 2002, 288(17):2130-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/abciximab-drug-information/abstract-text/12413372/pubmed\" target=\"_blank\" id=\"12413372\">12413372</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lincoff AM, Tcheng JE, Califf RM, et al, &ldquo;Sustained Suppression of Ischemic Complications of Coronary Intervention by Platelet GP IIb/IIIa Blockade With Abciximab: One-Year Outcome in the EPILOG Trial. Evaluation in PTCA to Improve Long-Term Outcome With Abciximab GP IIb/IIIa Blockade,&rdquo; <i>Circulation</i>, 1999, 99(15):1951-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/abciximab-drug-information/abstract-text/10208997/pubmed\" target=\"_blank\" id=\"10208997\">10208997</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Llevadot J, Coulter SA, and Giugliano RP, &ldquo;A Practical Approach to the Diagnosis and Management of Thrombocytopenia Associated With Glycoprotein IIb/IIIa Receptor Inhibitors,&rdquo; <i> J Thromb Thrombolysis</i>, 2000, 9(2):175-80.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/abciximab-drug-information/abstract-text/10613999/pubmed\" target=\"_blank\" id=\"10613999\">10613999</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mascelli MA, Lance ET, Damaraju L, et al, &ldquo;Pharmacodynamic Profile of Short-Term Abciximab Treatment Demonstrates Prolonged Platelet Inhibition With Gradual Recovery from GP IIb/IIIa Receptor Blockade,&rdquo; <i>Circulation</i>, 1998, 97(17):1680-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/abciximab-drug-information/abstract-text/9591761/pubmed\" target=\"_blank\" id=\"9591761\">9591761</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Miller RK, Mace K, Polliotti B, DeRita R, Hall W, Treacy G. Marginal transfer of ReoPro (Abciximab) compared with immunoglobulin G (F105), inulin and water in the perfused human placenta in vitro. <i>Placenta</i>. 2003;24(7):727-738.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/abciximab-drug-information/abstract-text/12852863/pubmed\" target=\"_blank\" id=\"12852863\">12852863</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Moliterno DJ, Yakubov SJ, DiBattiste PM, et al, &ldquo;Outcomes at 6 months for the Direct Comparison of Tirofiban and Abciximab During Percutaneous Coronary Revascularization With Stent Placement: The TARGET Follow-up Study.&rdquo; <i>Lancet</i>, 2002, 360(9330):355-60.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/abciximab-drug-information/abstract-text/12241774/pubmed\" target=\"_blank\" id=\"12241774\">12241774</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"11419426\"></a>Montalescot G, Barragan P, Wittenberg O, et al; ADMIRAL Investigators. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. <i>N Engl J Med</i>. 2001;344(25):1895-1903.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/abciximab-drug-information/abstract-text/11419426/pubmed\" target=\"_blank\" id=\"11419426\">11419426</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23247304\"></a>O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines [published correction appears in <i>Circulation</i>. 2013;128(25):e481.] <i>Circulation</i>. 2013;127(4):e362-425.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/abciximab-drug-information/abstract-text/23247304/pubmed\" target=\"_blank\" id=\"23247304\">23247304</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Osende JI, Fuster V, Lev EI, et al, &ldquo;Testing Platelet Activation With a Shear-Dependent Platelet Function Test Versus Aggregation-Based Tests: Relevance for Monitoring Long-Term Glycoprotein IIb/IIIa Inhibition,&rdquo; <i>Circulation</i>, 2001, 103(11):1488-91.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &ldquo;Platelet Glycoprotein IIb/IIIa Receptor Blockade and Low-Dose Heparin During Percutaneous Coronary Revascularization. The EPILOG Investigators,&rdquo; <i>N Engl J Med</i>, 1997, 336(24):1689-96.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/abciximab-drug-information/abstract-text/9182212/pubmed\" target=\"_blank\" id=\"9182212\">9182212</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &ldquo;Randomised Placebo-Controlled Trial of Abciximab Before and During Coronary Intervention in Refractory Unstable Angina: The CAPTURE Study,&rdquo; <i>Lancet</i>, 1997, 349(9063):1429-35.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/abciximab-drug-information/abstract-text/9164316/pubmed\" target=\"_blank\" id=\"9164316\">9164316</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    ReoPro (abciximab) [prescribing information]. Horsham, PA: Janssen Biotech Inc; May 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Santiago-D&iacute;az P, Arrebola-Moreno AL, Ram&iacute;rez-Hern&aacute;ndez JA, Melgares-Moreno R. Platelet antiaggregants in pregnancy. <i>Rev Esp Cardiol</i>. 2009;62(10):1197-1198. English, Spanish.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/abciximab-drug-information/abstract-text/19793530/pubmed\" target=\"_blank\" id=\"19793530\">19793530</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schr&ouml;r K and Weber A, &ldquo;Comparative Pharmacology of GP IIb/IIIa Antagonists,&rdquo; <i>J Thromb Thrombolysis</i>, 2003, 15(2):71-80<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/abciximab-drug-information/abstract-text/14618072/pubmed\" target=\"_blank\" id=\"14618072\">14618072</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sebastian C, Scherlag M, Kugelmass A, Schechter E. Primary stent implantation for acute myocardial infarction during pregnancy: use of abciximab, ticlopidine, and aspirin. <i>Cathet Cardiovasc Diagn</i>. 1998;45(3):275-279.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/abciximab-drug-information/abstract-text/9829887/pubmed\" target=\"_blank\" id=\"9829887\">9829887</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sinnaeve PR, Alexander JH, Bogaerts K, et al, &quot;Efficacy of Tenecteplase in Combination With Enoxaparin, Abciximab, or Unfractionated Heparin: One-Year Follow-Up Results of the Assessment of the Safety of a New Thrombolytic-3 (ASSENT-3) Randomized Trial in Acute Myocardial Infarction,&quot; <i>Am Heart J</i>, 2004, 147:993-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/abciximab-drug-information/abstract-text/15199346/pubmed\" target=\"_blank\" id=\"15199346\">15199346</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"11919304\"></a>Stone GW, Grines CL, Cox DA, et al; Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Investigators. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. <i>N Engl J Med</i>. 2002;346(13):957-966.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/abciximab-drug-information/abstract-text/11919304/pubmed\" target=\"_blank\" id=\"11919304\">11919304</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"22447888\"></a>Stone GW, Maehara A, Witzenbichler B, et al, &ldquo;Intracoronary Abciximab and Aspiration Thrombectomy in Patients With Large Anterior Myocardial Infarction: The INFUSE-AMI Randomized Trial,&quot; <i>JAMA</i>, 2012, 307(17):1817-26<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/abciximab-drug-information/abstract-text/22447888/pubmed\" target=\"_blank\" id=\"22447888\">22447888</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tcheng JE, Kereiakes DJ, Lincoff AM, et al, &ldquo;Abciximab Readministration: Results of the ReoPro&reg; Readministration Registry,&rdquo; <i>Circulation</i>, 2001, 104(8):870-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/abciximab-drug-information/abstract-text/11514371/pubmed\" target=\"_blank\" id=\"11514371\">11514371</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"22357109\"></a>Thiele H, W&ouml;hrle J, Hambrecht R, et al, &ldquo;Intracoronary Versus Intravenous Bolus Abciximab During Primary Percutaneous Coronary Intervention in Patients With Acute ST-elevation Myocardial Infarction: A Randomised Trial,&rdquo; <i>Lancet</i>, 2012, 379(9819):923-31.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/abciximab-drug-information/abstract-text/22357109/pubmed\" target=\"_blank\" id=\"22357109\">22357109</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Topol EJ, Ferguson JJ, Weisman HF, et al, &ldquo;Long-Term Protection From Myocardial Ischemic Events in a Randomized Trial of Brief Integrin Beta<sub>3</sub> Blockade With Percutaneous Coronary Intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complication,&rdquo; <i>JAMA</i>, 1997, 278(6):479-84.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/abciximab-drug-information/abstract-text/9256222/pubmed\" target=\"_blank\" id=\"9256222\">9256222</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Topol EJ, GUSTO V Investigators, &ldquo;Reperfusion Therapy for Acute Myocardial Infarction With Fibrinolytic Therapy or Combination Reduced Fibrinolytic Therapy and Platelet Glycoprotein IIb/IIIa Inhibition: The GUSTO V Randomized Trial,&rdquo; <i>Lancet</i>, 2001, 357(9272):1905-14.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/abciximab-drug-information/abstract-text/11425410/pubmed\" target=\"_blank\" id=\"11425410\">11425410</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Topol E, Moliterno DJ, Herrmann HC, et al, &ldquo;Comparison of Two Platelet Glycoprotein IIb/IIIa Inhibitors, Tirofiban and Abciximab, for the Prevention of Ischemic Events With Percutaneous Coronary Revascularization,&rdquo; <i>N Engl J Med</i>, 2001, 244:1888-94.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Trivedi SM, Shani J, and Hollander G, &ldquo;Bleeding Complications of Platelet Glycoprotein IIb/IIIa Inhibitor Abciximab (ReoPro&reg;),&rdquo; <i>J Invasive Cardiol</i>, 2002, 14(7):423-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/abciximab-drug-information/abstract-text/12082199/pubmed\" target=\"_blank\" id=\"12082199\">12082199</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &ldquo;Use of a Monoclonal Antibody Directed Against the Platelet Glycoprotein IIb/IIIa Receptor in High-Risk Coronary Angioplasty. The EPIC Investigation,&rdquo; <i>N Engl J Med</i>, 1994, 330(14):956-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/abciximab-drug-information/abstract-text/8121459/pubmed\" target=\"_blank\" id=\"8121459\">8121459</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vahdat B, Canavy I, Fourcade L, et al, &ldquo;Fatal Cerebral Hemorrhage and Severe Thrombocytopenia During Abciximab Treatment,&rdquo; <i>Catheter Cardiovasc Interv</i>, 2000, 49(2):177-80.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/abciximab-drug-information/abstract-text/10642768/pubmed\" target=\"_blank\" id=\"10642768\">10642768</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    van den Merkhof LF, Zijlstra F, Olsson H, et al, &ldquo;Abciximab in the Treatment of Acute Myocardial Infarction Eligible for Primary Percutaneous Transluminal Coronary Angioplasty. Results of the Glycoprotein Receptor Antagonist Patency Evaluation (GRAPE) Pilot Study,&rdquo; <i>J Am Coll Cardiol</i>, 1999, 33(6):1528-32.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/abciximab-drug-information/abstract-text/10334418/pubmed\" target=\"_blank\" id=\"10334418\">10334418</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wandt H, Frank M, Ehninger G, et al, &ldquo;Safety and Cost Effectiveness of a 10 X 10<sup>9</sup>/L Trigger for Prophylactic Platelet Transfusions Compared With the Traditional 20 X 10<sup>9</sup>/L Trigger: A Prospective Comparative Trial in 105 Patients With Acute Myeloid Leukemia,&rdquo; <i>Blood</i>, 1998, 91(10):3601-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/abciximab-drug-information/abstract-text/9572994/pubmed\" target=\"_blank\" id=\"9572994\">9572994</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9204 Version 143.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F128991\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F128992\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F129024\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F128994\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F128995\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F15671238\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F15671239\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F128975\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F128960\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F128978\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Usual Infusion Concentrations: Adult\" href=\"#F14471247\" class=\"outlineLink\">Usual Infusion Concentrations: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F128976\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25483778\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F5174499\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F128967\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F128981\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F128964\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298628\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F128969\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F128971\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F128983\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F20517875\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F128973\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F128963\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F128980\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16322956\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F128984\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9204|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=abciximab-patient-drug-information\" class=\"drug drug_patient\">Abciximab: Patient drug information</a></li></ul></div></div>","javascript":null}